香港股市 已收市

InMed Pharmaceuticals Inc. (MWG0.F)

Frankfurt - Frankfurt 延遲價格。貨幣為 EUR。
加入追蹤清單
0.2015-0.0005 (-0.25%)
收市:08:05AM CEST

InMed Pharmaceuticals Inc.

815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4
Canada
604 669 7207
https://www.inmedpharma.com

版塊Healthcare
行業Biotechnology
全職員工13

高階主管

名稱頭銜支付行使價出生年份
Mr. Eric A. Adams B.S. Chem., M.I.B.President, CEO & Director324.43k1963
Mr. Michael Woudenberg P.Eng.Chief Operating Officer268.2k1969
Ms. Alexandra Diane-Janet Mancini M.Sc.Senior Vice President of Clinical & Regulatory Affairs260.6k1953
Dr. Sazzad Hossain M.Sc., Ph.D.Co-Founder125.26k1958
Ms. N. Netta JagpalCFO & Corporate Secretary1973
Ms. Sarah Li CPA, CGAVP of Accounting & Controller
Colin ClancySenior Director of Investor Relations
Mr. Jerry P. GriffinVice President of Sales & Marketing
Dr. Eric Chih-Hsien HsuSenior Vice President of Preclinical Research & Development236.41k1970
Dr. Shane A. Johnson Ph.D.Senior VP & GM of BayMedica
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

公司管治

截至 無 止,InMed Pharmaceuticals Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。